Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vilazodone - AbbVie

Next Previous
Search
Drug Profile

Vilazodone - AbbVie

Alternative Names: EMD-68843; SB-659746A; Viibryd; Vilazodone hydrochloride

Latest Information Update: 06 Dec 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck KGaA
  • Developer AbbVie; Allergan; m8 Pharmaceuticals
  • Class Amides; Antidepressants; Benzofurans; Indoles; Nitriles; Piperazines; Small molecules
  • Mechanism of Action 5-HT1A serotonin receptor agonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Major depressive disorder
  • Phase III Generalised anxiety disorder
  • Phase II Social phobia
  • No development reported Sexual function disorders

Most Recent Events

  • 04 Dec 2023 m8 Pharmaceuticals has been acquired by Acino
  • 15 Apr 2021 Discontinued - Phase-III for Major depressive disorder (In adolescents, In children) in Canada (PO)
  • 08 May 2020 Allergan has been acquired and merged into AbbVie

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top